CLINICAL SCIENCE

Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device

E Goto, Y Monden, Y Takano, A Mori, S Shimmura, J Shimazaki, K Tsubota

Aim: To test the short term efficacy and safety of an infrared warm compression device (IWCD, Eye Hot, Cept Co, Tokyo, Japan) as treatment for non-inflamed meibomian gland dysfunction (MGD).

Methods: 37 subjects with non-inflamed obstructive MGD, with and without aqueous tear deficiency (ATD) dry eye, participated in a prospective non-comparative interventional case series. Symptom scores, face scores, tear evaporation rates, fluorescein and rose bengal vital staining, tear break up time (BUT), Schirmer test, meibomian gland obstruction, and meibography were compared before and after 2 weeks of therapy.

Results: In a total of 37 cases, total subjective symptom scores and subjective face scores improved significantly, from 12.3 (SD 5.9) to 8.4 (6.1), and from 7.0 (1.7) to 5.3 (2.0) (both p <0.0001). The results for tear evaporation rates during forced blinking (p = 0.002), fluorescein staining (p = 0.03), rose bengal staining (p = 0.03), BUT (p <0.0001), and meibomian gland orifice obstruction score (p <0.0001) had also improved significantly at the end of the 2 week period of infrared thermotherapy. No complaints and/or complications of the IWCD were reported.

Conclusion: The IWCD was effective and safe for the treatment of MGD. Improved tear stability associated with release of meibum is a possible mechanism of this treatment.

The meibomian glands secrete lipid into tears, and the lipid forms the oily layer of the precorneal tear film. This layer is responsible for preventing excessive evaporation of tears, for the barrier function at the lid margin, for lubrication during blinking, and for maintaining a smooth optical surface.\(^1\)

Non-inflamed obstructive meibomian gland dysfunction (MGD) is the major cause of lipid tear deficiency (LTD) or evaporative dry eye, and has recently attracted attention as a cause of ocular discomfort.\(^2 \)\(^,\)\(^3\) MGD decreases the supply of normal lipid, which leads to increased tear evaporation, decreased tear stability, loss of lubrication, and damage to the ocular surface epithelium, resulting in symptoms.\(^4 \)\(^,\)\(^5\)

The conventional treatment for MGD and blepharitis includes warm compression, lid hygiene, and topical or systemic medications.\(^6 \)\(^,\)\(^7\) However, as the therapeutic efficacy of conventional warm compression is variable and this treatment must be continued over a long period of time to achieve satisfactory reduction of symptoms, patients often discontinue treatment. Therefore, a more convenient method of performing warm compression is necessary to improve patient compliance. We have preliminarily reported that an infrared warm compression device (IWCD, Eye Hot, Cept Co, Tokyo, Japan) was a safe and effective device for warming the eyelids in normal volunteers, and that it allows subjects to perform warm compression without any preparation by simply connecting the device to a power supply.\(^8\)

In this study, we assessed the short term clinical efficacy and safety of the IWCD for the treatment of MGD.

MATERIALS AND METHODS

Subjects and inclusion criteria for MGD

We examined a series of 37 consecutive subjects with MGD (seven males, mean age 51.0 (SD 22.2) years, and 30 females, mean age 50.9 (13.3) years) at Tokyo Dental College, Ichikawa General Hospital.

These MGD subjects had already tried the conventional treatment for MGD in their follow up, such as the lid hygiene programme with warm compression or without topical antibiotics and/or steroids, and/or oral tetracycline. MGD subjects with no satisfactory relief of ocular symptoms, such as dry eye sensation, ocular fatigue, ocular pain, foreign body sensation, irritation, burning sensation or itchiness with those treatments, participated in this study. After the conventional treatment had been found to be ineffective in improving symptoms, the subjects had been followed up with the preservative-free artificial tears (Soft Santear, Santen Pharmaceutical, Osaka, Japan). Seven of 37 subjects (19%) dropped out of the lid hygiene programme with conventional warm compression.

Criteria for the diagnosis of non-inflamed obstructive meibomian gland dysfunction included the presence of meibomian gland dropout by meibography via transillumination through the tarsus, no or poor meibum expression by digital compression, and no or negligible inflammation in the lid margin.\(^9 \)\(^,\)\(^10\) Transillumination examination (meibography) with a fibreoptic device (L-3920, Inami, Co, Tokyo, Japan) was performed,\(^11\) and the degree of meibomian gland dropout was scored as described previously: grade 0, no gland dropout; grade 1, gland dropout in less than half of the inferior tarsus; grade 2, gland dropout in more than half of the inferior tarsus.\(^12\)\(^,\)\(^13\)

To assess meibum expression and meibomian gland orifice obstruction, digital pressure was applied to the upper tarsus, and the degree of ease of expression of meibomian secretions (meibum) was evaluated semiquantitatively as follows: grade 0, clear meibum easily expressed; grade 1, cloudy meibum expressed with mild pressure; grade 2, cloudy meibum expressed with more than moderate pressure; and grade 3, meibum cannot be expressed even with strong pressure.\(^14\) Patients with a meibography score of grade 1 or 2 and a meibomian gland orifice obstruction score of 2 or 3 were diagnosed as having MGD.

Five of the subjects had Sjögren’s syndrome and eight had a previous history of allergic conjunctivitis (but no active inflammation or itchiness during the study period).\(^15\) There were 17 subjects with a Schirmer test value of less than 5 mm, indicating that they had non-inflamed obstructive MGD complicated by aqueous tear deficiency (ATD),\(^16\) while 20 patients...
had Schirmer test values equal to or greater than 6 mm. Analysis was done among all 37 MGD subjects, and MGD patients with and without ATD, separately. Only the right eye was used for analysis. Eyes with anterior blepharitis of moderate or greater severity, infectious conjunctivitis, eyes with an occluded punctum, and contact lens wearers were excluded from the study. Also, subjects with best corrected visual acuity less than 1.0 and obvious eyelid skin abnormalities, such as atopic dermatitis, were excluded. Current topical medication (preservative-free artificial tear eye drops) was also recorded throughout the study. Information consent was obtained from all subjects, and institutional review board/ethics committee approval was not required for this study.

**Assessment of symptoms, tears, ocular surface, and meibomian glands**

After a general ocular examination, the following examinations were carried out in the order listed to prevent the procedures from affecting each other: subjective symptoms, subjective face scores, tear evaporation test, fluorescein and rose bengal vital staining, measurement of BUT, Schirmer test, meibomian gland assessment, and meibomography. Best corrected visual acuity was more than 1.0 in decimal notation in all subjects, and lens opacities were recorded according to the method of Taylor and West.

**Table 1** Temperature change of the cornea and upper eyelid in Japanese hot baths and IWCD use (mean (SD))

<table>
<thead>
<tr>
<th></th>
<th>Cornea (°C)</th>
<th>Upper eyelid (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal volunteers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n = 5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room temperature</td>
<td>34.8 (0.9)</td>
<td>35.0 (0.7)</td>
</tr>
<tr>
<td>(22.5°C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In Japanese hot bath</td>
<td>38.4 (0.3)</td>
<td>38.2 (0.5)</td>
</tr>
<tr>
<td>5 minutes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(water temperature,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41.5°C, bathroom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>temperature 26.4°C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IWCD 5 minutes</td>
<td>37.9 (0.9)</td>
<td>38.0 (0.7)</td>
</tr>
<tr>
<td>Room temperature</td>
<td>36.5 (0.8)</td>
<td>35.8 (0.7)</td>
</tr>
<tr>
<td>(22.5°C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IWCD 5 minutes</td>
<td>38.2 (0.9)</td>
<td>37.4 (0.9)</td>
</tr>
<tr>
<td>Room temperature</td>
<td>34.1 (1.2)</td>
<td>34.1 (0.8)</td>
</tr>
<tr>
<td>(23.0°C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IWCD 5 minutes</td>
<td>36.1 (1.4)</td>
<td>37.3 (1.2)</td>
</tr>
<tr>
<td>MGD subjects (n = 3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room temperature</td>
<td>37.9 (0.9)</td>
<td>38.0 (0.7)</td>
</tr>
<tr>
<td>(22.5°C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IWCD 5 minutes</td>
<td>38.2 (0.9)</td>
<td>37.4 (0.9)</td>
</tr>
</tbody>
</table>

IWCD = infrared warm compression device.

**Device for warm compression**

The IWCD was adopted for convenient warm compression therapy. Briefly, the IWCD is composed of two hard eye patches that are attached to the eye mask according to the pupillary distance of the subject. The eye mask is held in place by an elastic headband. Each patch has 19 light emitting diodes, emitting near infrared radiation from 850 to 1050 nm, with a peak at 940 nm. It produces approximately 10 mW/cm² of energy, operating on electrical power. Previously, we reported the safety and efficacy of the IWCD on 10 normal subjects using non-contact infrared radiation thermography and the subjects' comfort with the face score. In this study, the device was applied to all 37 MGD subjects for 5 minutes, after 2 minutes of preheating, twice a day for 2 weeks, with the eyelids closed.

**Temperature change of the eye using the device**

When we use near infrared radiation for ocular surface treatment with closed eyelids, thermal cataract formation could be a concern. To assess the temperature change of the cornea and eyelids during normal daily activities and while using the IWCD (wave length peak, 940 nm), we measured the temperature of the eye using an infrared radiation thermometer (THI-5005, Tasco Japan, Osaka, Japan) for 5 normal volunteers and 3 MGD subjects, and also compared to the data from our previous report. The typical water temperature of Japanese hot baths (usual home bath, not a hot spring) is around 42°C. The temperature of the cornea and upper eyelid was almost identical in both the Japanese hot baths and while using the IWCD, so the temperature change for 5 minutes of use of the IWCD was within the range of normal daily activities.
RESULTS

The results of this study are summarised in Table 2. In a total of 37 cases, each scored symptom significantly improved except for the burning sensation (dry eye sensation) from 2.6 (1.5) to 1.9 (1.4), p = 0.03, ocular fatigue from 2.9 (1.2) to 1.9 (1.2), p < 0.0001, ocular pain from 1.9 (1.5) to 1.3 (1.3), p = 0.002, foreign body sensation from 1.6 (1.5) to 1.0 (1.2), p = 0.01, irritation from 2.1 (1.7) to 1.5 (1.4), p = 0.03, burning sensation from 0.6 (1.2) to 0.4 (0.9), p = 0.1, and itchiness from 0.7 (0.7) to 0.5 (0.7), p = 0.02, respectively. Total subjective symptom scores and subjective face scores improved significantly after 2 weeks of therapy. Tear evaporation rates during normal blinking did not change significantly after treatment. Tear evaporation rates during forced blinking decreased significantly, from 22.1 (11.9) (10^{-7} g/s) to 16.2 (10.6) (10^{-7} g/s), p = 0.002, Fig 1). Vital staining score improved significantly (fluorescein score from 2.5 (2.3) to 1.7 (1.8), p = 0.03 and rose Bengal score from 1.8 (2.5) to 1.1 (2.1), p = 0.03, respectively). BUT was also prolonged significantly. The Schirmer test values and meibography scores did not change significantly. The meibomian gland orifice obstruction score improved, from 2.3 (0.7) to 0.8 (0.8) (p < 0.0001, Fig 2A and B).

When the results were compared in MGD cases with and without ATD separately (Table 2), in 17 MGD cases with ATD, total subjective symptom scores and subjective face scores also improved significantly. Tear evaporation rates during both normal blinking and forced blinking did not show significant change after treatment. Rose bengal staining score showed significant improvement from 3.2 (3.0) to 2.1 (2.8) (p = 0.04). On the contrary, fluorescein staining scores did not significantly change. BUT improved significantly. The meibomian gland obstruction score improved, from 2.4 (1.7) to 1.0 (1.0), p = 0.01. The Schirmer test values and meibography scores did not change significantly. The meibomian gland orifice obstruction score improved, from 2.3 (0.7) to 0.8 (0.8) (p < 0.0001, Fig 2A and B).

Figure 1 Results of tear evaporation rates during normal blinking and forced blinking in 37 cases with MGD. The difference in tear evaporation rates during normal blinking after 2 weeks of therapy was not significant, but the difference in evaporation during forced blinking was significant (*p = 0.002) in all 37 cases with MGD.
gland orifice obstruction scores improved, from 2.1 (0.7) to 0.8 (0.8) (p <0.0001).

Similarly, in 20 MGD cases without ATD, total subjective symptom scores and subjective face scores improved. Tear evaporation rates during normal blinking did not change significantly after treatment, but evaporation during forced blinking decreased significantly, from 24.9 (13.5) (10^-7 g/s) to 17.5 (12.4) (10^-7 g/s, p = 0.02). Fluorescein and rose bengal staining score did not show significant change. On the other hand, BUT improved significantly. The meibomian gland orifice obstruction score improved, from 2.5 (0.6) to 0.9 (0.7) (p < 0.0001).

No complaints attributable to the IWCD were reported. No complications, such as lid skin dermatitis, anterior chamber inflammation, decreased visual acuity, or cataract formation were observed over the 2 week duration of this study.

**DISCUSSION**

This study demonstrated a clear benefit of using the IWCD to treat MGD. Since MGD is a major cause of ocular irritation, relief of symptoms is an essential goal of treatment. All measured symptoms (dry eye sensation, ocular fatigue, ocular pain, foreign body sensation, irritation, and itchiness) except burning sensation showed significant improvement. Also, ocular discomfort as checked by the subjective face score decreased.

Objective findings, including tear evaporation, BUT, fluorescein staining, rose bengal staining, and MG orifice obstruction improved in all 37 cases. No subjective complaints or objective complications as a result of IWCD use were noted after 2 weeks of therapy with the IWCD, indicating that it is a safe device, and all subjects continued to use it for 2 weeks with no dropout during the treatment period. Since the use of the IWCD is more convenient than conventional warm compression, we were able to achieve good compliance with this therapy. In addition, the IWCD is portable and can be used wherever electricity is available, such as in the office after visual display terminal work, even if the subject worked in an active office.

Tear stability, tear evaporation, and meibum expression all improved. The improved tear evaporation during forced blinking, which was observed in the comparison in all 37 cases as well as in the 20 cases of MGD without ATD, suggests that meibum was released by infrared heating, spread well to form a stable lipid layer, and decreased the evaporation. No significant change of tear evaporation was observed in 20 MGD patients without ATD subjects. This might suggest that subjects without a proper aqueous amount could not form the lipid film to decrease evaporation even though they had improved lipid expression. Tear evaporation rates measured during forced blinking every 5 seconds may be a more sensitive means of detecting the abnormal tear lipid layer of MGD. MGD patients may compensate for dryness and increased tear evaporation by frequent blinking in the measurement of tear evaporation with normal blinking. In this study the blink rate measured during the evaporation examination with normal blinking was 24.0 (11.0)/min in all 37 MGD patients, while the blink rate was reported as 14.3/min in normal subjects and 33.9/min in dry eye patients. Although not performed in this study, adding lid massage to warm compression could suppress the evaporation even more during the evaporation measurement with normal blinking. Tear evaporation rates were used for the first time to evaluate the efficacy of treating MGD. To directly assess the change in the tear lipid layer on the cornea after the treatment, further development of tear interference image for quantification of the lipid layer in MGD is expected.

The mechanism of the decrease in meibomian gland orifice obstruction using IWCD is unclear. McCulley et al. found that meibomian secretions with ester fractions of different composition can have different melting points, and that chronic blepharitis can cause a shift towards lipid with higher melting points, producing a stagnant, and less dynamic, tear film. Heating the eye and eyelids with the IWCD is speculated to melt the obstructed meibomian gland lipid easily, similar to the previous warm compression, as infrared has been used for effective hyperthermia. This may lead to the improvement of tear stability indicated by BUT. Also, this infrared heater was reported to have the advantage of warming the eyelid effectively and safely with its strong emission at 940 nm, compared to the traditional Asian eye warming instrument using the wide range (200–6000 nm) electric light bulb. Infrared between 800 and 1200 nm easily passes through skin and is mostly absorbed in the underlying 1–3 mm of tissue.

It has been considered that an unstable tear film in MGD patients leads to epithelial damage as shown by fluorescein and rose bengal vital staining. IWCD treatment was also effective in reducing the damage to the cornea and conjunctival epithelium, in all 37 cases. However, these effects were limited when we analysed the results separately between MGD with and without ATD, showing significant improvement only in the rose bengal scores of MGD subjects with ATD.

No significant changes in the Schirmer test values or meibography scores were reported after 2 weeks of treatment. Thus, the IWCD did not change the tear secretion from the lacrimal gland and visible structure of meibomian gland of MGD patients.

Although the safety of the IWCD with near infrared radiation with the eyelids closed has been described previously, and although infrared radiation has been used for transpupillary thermotherapy, near infrared radiation could cause damage to the eye, especially thermal cataract formation. Thus, the temperature change in use of the IWCD is important. In this study, we compared the temperature change in both 5 minutes of use of the IWCD and 5 minutes of taking a Japanese hot bath, and the change was found to be identical. Although a long term study for the safety of the device would be required, we considered that the device was
safe for at least 2 weeks of use, as the range of temperature change was within normal daily activities. As for the skin, the first step of thermal injury to human skin occurs in temperatures under 44°C of the surface temperature of the skin. Since eyelid temperature after IWC with application never beyond 39.7°C, is unlikely to cause thermal injury to the skin by using the IWC.\(^7\) Application of the treatment in this study was limited to non-inflamed MGD with and without ATD. We have no experience with this treatment for MGD with active inflammation, such as meibomitis and blepharitis, and conventional therapy should be tried first for these diseases. Also, if we use the conventional medication, such as topical antibiotics, with IWC for the treatment of MGD, it could be more effective. In summary, we found that the IWC was effective and safe in the treatment of MGD after 2 weeks of therapy. Improvement of tear stability associated with the release of meibum was considered to be responsible for its therapeutic effect.

ACKNOWLEDGEMENTS

Supported by grants from the Japanese Ministry of the Economy, Education, and Science, Tokyo, the Medical School Faculty and Alumni Grants of Keio University Medical School, Tokyo, and the Hightech Research Center at Tokyo Dental College, Chiba, Japan. The authors thank Co. Tokyo, Japan, for its assistance in developing the infrared warm compression device, “Eye Hot.”

Financial disclosure: Patent pending for infrared warm compression device by Kazuo Tsutbota, MD.

Authors’ affiliations
E Goto, Y Takano, S Shimmura, J Shimazaki, K Tsubota, Tokyo Dental College, Department of Ophthalmology, Chiba, Japan
E Goto, Y Takano, A Mori, S Shimmura, K Tsubota, Keio University, Department of Ophthalmology, Tokyo, Japan
Y Monden, Kurume University, Department of Ophthalmology, Kurume, Japan

REFERENCES

Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device
E Goto, Y Monden, Y Takano, A Mori, S Shimmura, J Shimazaki and K Tsubota

Br J Ophthalmol 2002 86: 1403-1407
doi: 10.1136/bjo.86.12.1403

Updated information and services can be found at:
http://bjo.bmj.com/content/86/12/1403

These include:

References
This article cites 42 articles, 8 of which you can access for free at:
http://bjo.bmj.com/content/86/12/1403#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/